Alnylam Pharmaceuticals (ALNY) reported $1.1 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 84.9%. EPS of $1.25 for the same period compares to $0.06 a year ago.
The reported revenue represents a surprise of -3.35% over the Zacks Consensus Estimate of $1.14 billion. With the consensus EPS estimate being $1.16, the EPS surprise was +8.16%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Product Revenue- Onpattro- United States: $12.02 million versus $5.37 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -39.7% change.
- Net Product Revenue- Oxlumo- United States: $17.61 million versus $23.94 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.1% change.
- Net Product Revenue- Givlaari- United States: $56.34 million compared to the $47.24 million average estimate based on two analysts. The reported number represents a change of +25.1% year over year.
- Net Product Revenue- Amvuttra- United States: $641.57 million versus the two-analyst average estimate of $619.86 million. The reported number represents a year-over-year change of +250.1%.
- Revenues- Product revenues, net: $994.72 million versus $1.01 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +120.6% change.
- Net Product Revenue- Givlaari: $86.8 million versus the six-analyst average estimate of $79.72 million. The reported number represents a year-over-year change of +34.3%.
- Revenues- Net revenues from research collaborators: $40.94 million compared to the $94.22 million average estimate based on six analysts. The reported number represents a change of -61.7% year over year.
- Net Product Revenue- Total Rare: $136.44 million compared to the $134.95 million average estimate based on six analysts.
- Net Product Revenue- Oxlumo: $49.65 million versus the six-analyst average estimate of $55.23 million. The reported number represents a year-over-year change of +13.9%.
- Revenues- Royalty revenue: $61.37 million versus $55.64 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +73.4% change.
- Net Product Revenue- Onpattro: $31.69 million compared to the $39.82 million average estimate based on five analysts. The reported number represents a change of -43.5% year over year.
- Net Product Revenue- Amvuttra: $826.59 million compared to the $837.17 million average estimate based on five analysts. The reported number represents a change of +188.5% year over year.
View all Key Company Metrics for Alnylam here>>>
Shares of Alnylam have returned -12.2% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
